Grey Wolf Therapeutics is a UK and Australian-based drug discovery and development company that specializes in next-generation immunotherapies. Unlike traditional approaches that target the immune system, Grey Wolf focuses on directly altering tumor cells to make them visible to the immune system for destruction. They are developing small molecules that inhibit the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which are involved in the antigen presentation pathway.

By inhibiting these enzymes, Grey Wolf enhances the antigen repertoire within tumor cells, significantly increasing tumor visibility and extending the efficacy of immunotherapy in oncology. The company collaborates with leading academic and commercial partners in drug discovery and development, including The University of Oxford, Monash University, and University of Southampton. Grey Wolf is dedicated to delivering first-in-class clinical candidates that overcome resistance mechanisms and advance the field of immuno-oncology.

With a focus on teamwork, innovation, excellence, and momentum, Grey Wolf is committed to revolutionizing the next generation of oncology therapies